Novo, Partners Healthcare and Sham all contributed to a $74.6m round for Alizé Pharma 3, which is exploiting research from three US institutions.
Alizé Pharma 3, a France-based biopharmaceutical startup based on research at University of North Carolina (UNC) at Chapel Hill, University of Maine and Harvard University, secured €67m ($74.6m) on Tuesday in a series A round led by investment firm LSP.
Novo Ventures, Partners Innovation and Sham Innovation Santé, respective investment vehicles for pharmaceutical firm Novo, healthcare provider Partners Healthcare and insurer Sham, took part in the round.
Management consulting firm TAB and Crédit Agricole Creation, an investment vehicle…
